A Phase 2, Non-Randomized, Open-Label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Ramucirumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 14 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 23 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.